{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:10:02Z","timestamp":1777525802018,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["PO1 CA66726"],"award-info":[{"award-number":["PO1 CA66726"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.lungcan.2021.01.011","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:40:19Z","timestamp":1610624419000},"page":"5-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial"],"prefix":"10.1016","volume":"154","author":[{"given":"Sharyn I.","family":"Katz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-8835","authenticated-orcid":false,"given":"Leonid","family":"Roshkovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph S.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-3555","authenticated-orcid":false,"given":"Evan W.","family":"Alley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0867-3694","authenticated-orcid":false,"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Cengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H.","family":"Sterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Albelda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lungcan.2021.01.011_bib0005","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-04-2304","article-title":"Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients","volume":"11","author":"Ho","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2021.01.011_bib0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/2212697X03666160218215744","article-title":"Novel antibody therapeutics targeting mesothelin in solid tumors","volume":"3","author":"Zhao","year":"2016","journal-title":"Clin. Cancer Drugs"},{"issue":"34","key":"10.1016\/j.lungcan.2021.01.011_bib0015","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2021.01.011_bib0020","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2021.01.011_bib0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2007.12.025","article-title":"Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study","volume":"61","author":"Roe","year":"2008","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2021.01.011_bib0030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Schneider","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"44","key":"10.1016\/j.lungcan.2021.01.011_bib0035","doi-asserted-by":"crossref","first-page":"77872","DOI":"10.18632\/oncotarget.20845","article-title":"Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1","volume":"8","author":"Eguchi","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.lungcan.2021.01.011_bib0040","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"issue":"7","key":"10.1016\/j.lungcan.2021.01.011_bib0045","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/bjc.2015.62","article-title":"The south west area mesothelioma and pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication","volume":"112","author":"Hooper","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"9396","key":"10.1016\/j.lungcan.2021.01.011_bib0050","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lungcan.2021.01.011_bib0055","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.athoracsur.2017.06.042","article-title":"Soluble mesothelin-related peptides to monitor recurrence after resection of pleural mesothelioma","volume":"104","author":"Burt","year":"2017","journal-title":"Ann. Thorac. Surg."},{"issue":"10","key":"10.1016\/j.lungcan.2021.01.011_bib0060","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.lungcan.2021.01.011_bib0065","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: a potential test for malignant pleural mesothelioma","volume":"53","author":"Beyer","year":"2007","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.lungcan.2021.01.011_bib0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00408-016-9868-1","article-title":"Evaluation of new biomarkers in the prediction of malignant mesothelioma in subjects with environmental asbestos exposure","volume":"194","author":"Demir","year":"2016","journal-title":"Lung"},{"issue":"6","key":"10.1016\/j.lungcan.2021.01.011_bib0075","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","article-title":"Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma","volume":"181","author":"Hollevoet","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"13","key":"10.1016\/j.lungcan.2021.01.011_bib0080","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2021.01.011_bib0085","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0b013e31828f696b","article-title":"Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer","volume":"8","author":"Muley","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2021.01.011_bib0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","article-title":"Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions","volume":"85","author":"Pass","year":"2008","journal-title":"Ann. Thorac. Surg."},{"issue":"2","key":"10.1016\/j.lungcan.2021.01.011_bib0095","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/1055-9965.EPI-08-0422","article-title":"Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure","volume":"18","author":"Rodriguez Portal","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"10","key":"10.1016\/j.lungcan.2021.01.011_bib0100","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.01.011_bib0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12885-018-4113-3","article-title":"A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma","volume":"18","author":"de Fonseka","year":"2018","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2021.01.011_bib0110","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/carcin\/bgz103","article-title":"Biomarkers for malignant pleural mesothelioma: a meta-analysis","volume":"40","author":"Gillezeau","year":"2019","journal-title":"Carcinogenesis"},{"issue":"11","key":"10.1016\/j.lungcan.2021.01.011_bib0115","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2021.01.011_bib0120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0945-053X(99)00038-4","article-title":"Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4","volume":"18","author":"Giltay","year":"1999","journal-title":"Matrix Biol."},{"issue":"2","key":"10.1016\/j.lungcan.2021.01.011_bib0125","first-page":"402","article-title":"Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation","volume":"40","author":"Kim","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2021.01.011_bib0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070511","article-title":"Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis","volume":"8","author":"Luo","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lungcan.2021.01.011_bib0135","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/path.2776","article-title":"Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity","volume":"222","author":"Hwang","year":"2010","journal-title":"J. Pathol."},{"issue":"11","key":"10.1016\/j.lungcan.2021.01.011_bib0140","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1158\/1541-7786.MCR-09-0207","article-title":"Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion","volume":"7","author":"Hu","year":"2009","journal-title":"Mol. Cancer Res."},{"issue":"15","key":"10.1016\/j.lungcan.2021.01.011_bib0145","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"30","key":"10.1016\/j.lungcan.2021.01.011_bib0150","doi-asserted-by":"crossref","first-page":"21628","DOI":"10.18632\/oncotarget.25301","article-title":"Correction: diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis","volume":"9","author":"Pei","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.lungcan.2021.01.011_bib0155","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.3892\/ol.2016.5051","article-title":"Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells","volume":"12","author":"Rapisarda","year":"2016","journal-title":"Oncol. Lett."},{"issue":"51","key":"10.1016\/j.lungcan.2021.01.011_bib0160","doi-asserted-by":"crossref","first-page":"84851","DOI":"10.18632\/oncotarget.12707","article-title":"Diagnostic value of fibulin-3 for malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"7","author":"Ren","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.lungcan.2021.01.011_bib0165","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1515\/raon-2015-0019","article-title":"Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma","volume":"49","author":"Kovac","year":"2015","journal-title":"Radiol. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2021.01.011_bib0170","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis","volume":"113","author":"Kirschner","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2021.01.011_bib0175","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2021.01.011_bib0180","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.athoracsur.2012.02.009","article-title":"Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma","volume":"93","author":"Friedberg","year":"2012","journal-title":"Ann. Thorac. Surg."},{"issue":"3","key":"10.1016\/j.lungcan.2021.01.011_bib0185","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.athoracsur.2016.08.071","article-title":"Extended pleurectomy-decortication-Based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years","volume":"103","author":"Friedberg","year":"2017","journal-title":"Ann. Thorac. Surg."},{"issue":"15","key":"10.1016\/j.lungcan.2021.01.011_bib0190","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFNalpha combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2021.01.011_bib0195","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2019.08.012","volume":"14","author":"Gill","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.01.011_bib0200","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cpet.2011.04.001","article-title":"Multimodality imaging review of malignant pleural mesothelioma diagnosis and staging","volume":"6","author":"Gerbaudo","year":"2011","journal-title":"PET Clin."},{"issue":"1","key":"10.1016\/j.lungcan.2021.01.011_bib0205","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.rmed.2009.05.017","article-title":"Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis","volume":"104","author":"Luo","year":"2010","journal-title":"Respir. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2021.01.011_bib0210","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.18632\/oncotarget.14712","article-title":"Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis","volume":"8","author":"Pei","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lungcan.2021.01.011_bib0215","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1378\/chest.11-0129","article-title":"The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor","volume":"141","author":"Hollevoet","year":"2012","journal-title":"Chest"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:46:13Z","timestamp":1759236373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":43,"alternative-id":["S0169500221000295"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.01.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}